Generic Ilevro Availability
Last updated on Jan 8, 2025.
Ilevro is a brand name of nepafenac ophthalmic, approved by the FDA in the following formulation(s):
ILEVRO (nepafenac - suspension/drops;ophthalmic)
-
Manufacturer: HARROW EYE
Approval date: October 16, 2012
Strength(s): 0.3% [RLD]
Has a generic version of Ilevro been approved?
No. There is currently no therapeutically equivalent version of Ilevro available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ilevro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 7,947,295
Patent expiration dates:
- June 8, 2024✓
- June 8, 2024
-
Carboxyvinyl polymer-containing nanoparticle suspensions
Patent 8,921,337
Issued: December 30, 2014
Inventor(s): Chowhan Masood A. & Ghosh Malay & Asgharian Bahram & Han Wesley Wehsin
Assignee(s): Alcon Research, Ltd.The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.
Patent expiration dates:
- March 31, 2032✓
- March 31, 2032
-
Carboxylvinyl polymer-containing nanoparticle suspensions
Patent 9,662,398
Issued: May 30, 2017
Inventor(s): Chowhan Masood A. & Ghosh Malay & Asgharian Bahram & Han Wesley Weshin
Assignee(s): Alcon Research, Ltd.The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.
Patent expiration dates:
- December 1, 2030✓
- December 1, 2030
More about Ilevro (nepafenac ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (12)
- Side effects
- Dosage information
- During pregnancy or Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.